- Revenue: $714.9 million, a 20% increase year-over-year (y/y); estimate was $692 million.
- Net Tyvaso Sales: $398.2 million, a 25% increase y/y; estimate was $400.6 million.
- Net Remodulin Sales: $147.3 million, a 16% increase y/y; estimate was $129.1 million.
- Net Orenitram Sales: $107.1 million, a 13% increase y/y; estimate was $104.8 million.
- Net Unituxin Sales: $51.7 million, a 17% increase y/y; estimate was $53.2 million.
- Net Adcirca Sales: $5.7 million, a 24% decrease y/y; estimate was $6.06 million.
- EPS (Earnings Per Share): $5.85 versus $5.24 y/y; estimate was $6.50.
- R&D Expenses: $139.6 million, a 57% increase y/y; estimate was $114.3 million.
- Analyst Ratings: 10 buys, 3 holds, 2 sells.
United Therapeutics on Smartkarma
Analyst coverage of United Therapeutics on Smartkarma has highlighted positive sentiments from Baptista Research. In their report titled “United Therapeutics Corporation: Xenotransplantation Initiatives; Expansion into Pulmonary Hypertension Treatment & Other Major Drivers,” Baptista Research lauds the company’s robust financial results for the first quarter of 2024, showcasing strong growth and development in its product lines and research endeavors. The analysis focuses on a comprehensive strategy balancing growth, capital allocation, and product development, aiming to evaluate factors influencing the company’s future price through an independent valuation using a Discounted Cash Flow methodology.
Baptista Research‘s other report, “United Therapeutics Corporation: Initiation Of Coverage – 6 Biggest Factors Driving Its Future Growth! – Financial Forecasts,” emphasizes UTC’s solid financial performance in the fourth quarter of 2023, with record revenue and income marking consistent growth trends. The report underscores the company’s over 20% growth in both quarterly and annual revenue, reflecting a positive outlook for United Therapeutics Corporation’s future prospects as a biotech major.
A look at United Therapeutics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
United Therapeutics Corporation, a pharmaceutical company focusing on vascular disease treatments like pulmonary hypertension, shows a promising long-term outlook based on Smartkarma Smart Scores. The company scores high in Growth, Resilience, and Momentum, indicating strong potential for expansion, stability in challenging conditions, and positive market momentum. With a solid track record in developing stable synthetic prostacyclin products for oral and subcutaneous delivery, United Therapeutics is positioned for continued success in the pharmaceutical industry.
Despite a lower score in Dividend, the company’s strengths in Value, Growth, Resilience, and Momentum overshadow this factor. Investors considering United Therapeutics can be optimistic about its future performance, driven by its innovative product portfolio and the positive market sentiment reflected in the Smart Scores. Overall, United Therapeutics‘ focus on vascular disease treatments and its strong performance across key metrics make it an attractive prospect for long-term investment.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
